Jesus Herranz

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 3

Top Topics

Metastatic Breast Cancer

Patient Reported

Sentinel Lymph Node

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Angel L Guerrero-Zotano, Stefania Belli, Christoph C Zielinski, Juan Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz Borrego, Eva Ciruelos Gil, Javier Pascual, Montserrat Muñoz, Begoña Bermejo, Mireia Margelí, Antonio Antón-Torres, Laura Murillo, Bella Nisenbaum, Yuan Liu, Jesus Herranz, Daniel Fernandez-Garcia, Rosalía Caballero, Jose Antonio Lopez-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas C Turner, Miguel Martin
CCNE1 and PLK1 mediates resistance to palbociclib in HR+/HER2- metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Javier Pascual, Juan Miguel Gil-Gil, Paula Z Proszek, Christoph C Zielinski, Alistair Reay, Manuel Ruiz Borrego, Rosalind J Cutts, Eva Ciruelos Gil, Andrew Feber, Montserrat Muñoz, Claire Swift, Begoña Bermejo, Jesus Herranz, Mireia Margelí, Antonio Antón-Torres, Zsuzsanna Kahán, Tibor Csőszi, Yuan Liu, Daniel Fernandez-Garcia, Isaac Garcia-Murillas, Michael Hubank, Nicholas C Turner, Miguel Martin
Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Karama Asleh, Ana Lluch, Angela Goytain, Carlos Henrique Barrios, Xue Qi Wang, Laura Torrecillas, Dongxia Gao, Manuel Ruiz Borrego, Samuel C Y Leung, Jose Bines, Angel L Guerrero-Zotano, José Angel García-Saenz, Juan Miguel Cejalvo, Jesus Herranz, Roberto Torres, Juan R De la Haba-Rodríguez, Francisco Ayala, Henry L Gómez, Federico Rojo, Torsten O Nielsen, Miguel Martin
Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)